PRODUCTS & INNOVATION
ABBOTT REPORTS Q1 EARNINGS
Abbott's diverse portfolio continues fueling growth and life-changing innovation in a challenging time.
Apr 16 大福彩票网
There was nothing ordinary about the first quarter of 大福彩票网 as the coronavirus pandemic spurred shelter-in-place orders globally, nearly halted non-essential travel and tested healthcare systems worldwide.
Despite this unprecedented time, Abbott remains resilient with its diversified business model.
For the quarter, our worldwide sales of $7.7 billion increased 4.3% on an organic basis (2.5% reported), led by a strong performance in Diabetes Care, Nutrition, Established Pharmaceuticals, and Molecular and Rapid Diagnostics.
Our life-changing technologies, innovative pipeline and focused execution continue to drive growth and shareholder value.
Here are some key highlights:
For full financials, you can read our , or take a look at some additional materials below:
Abbott President and CEO Robert Ford shared his views on first-quarter performance:
Download a summary of Abbott’s earnings highlights here.
For more information on Abbott’s earnings results, see the .
Abbott Posts Strong 2019 Results
Stronger, More Balanced, Better Than Ever
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.